Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jorge E. Cortes, Samer Khaled, Giovanni Martinelli, Alexander E. Perl, Siddhartha Ganguly, Nigel Russell, Alwin Krämer, Hervé Dombret, Donna Hogge, Brian A. Jonas, Anskar Yu Hung Leung, Priyanka Mehta, Pau Montesinos, Markus Radsak, Simona Sica, Meena Arunachalam, Melissa Holmes, Ken Kobayashi, Ruth Namuyinga, Nanxiang GeAntoine Yver, Yufen Zhang, Mark J. Levis
Dive into the research topics of 'Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial'. Together they form a unique fingerprint.